Overview

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

Status:
Completed
Trial end date:
2016-09-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Levodopa